Glycoconjugation comes to BTEC
Published January 13, 2014
BTEC will offer Glycoconjugate Technology, LLC (Chapel Hill, NC) dedicated laboratory facilities and equipment so that the company can develop its novel glycoconjugate technology. Glycoconjugates used in some pediatric vaccines are produced by covalently linking a polysaccharide isolated from the cell wall of an infectious bacterium to a purified carrier protein. The glycoconjugate complex helps elicit an immune response to the polysaccharide, thus protecting the infant from disease.
According to Dr. Velupillai Puvanesarajah (Puvy), Glycoconjugate Technology’s founder, the company’s primary goal is to develop efficient chemical methods to produce conjugate vaccines at lower manufacturing cost. Dr. Puvy has worked in the vaccine industry for over twenty years and has won several prestigious awards for his pioneering work in the field of conjugate vaccines, most notably the “Heroes of Chemistry” award by the American Chemical Society in 2003 and the “National Medal of Technology” award in 2007.
BTEC is confident that the relationship will lead to additional development projects, new curricula, and growth of BTEC’s expertise in chemistry and formulation processes utilized in the vaccine industry.
For more information, please contact one of the following individuals.
Velupillai Puvanesarajah, PhD
Glycoconjugate Technology, LLC